KSE
Search
- Page Path
- HOME > Search
Original Article
- Bacillus of Calmette and Guérin (BCG) and the risk of leprosy in Ciudad del Este, Paraguay, 2016-2017
- Nancy Carolina Cuevas, Victor M. Cardenas
- Epidemiol Health. 2021;43:e2021060. Published online September 8, 2021
- DOI: https://doi.org/10.4178/epih.e2021060
- 22,099 View
- 123 Download
- 5 Web of Science
- 4 Crossref
-
Abstract
Summary
PDF -
AbstractOBJECTIVES
Paraguay has experienced a 35% reduction in the detected incidence of leprosy during the last ten years, as the vaccination coverage against tuberculosis (Bacillus of Calmette and Guérin [BCG] vaccine) reached ≥95% among infants. The objective of this case-control study was to evaluate the protective effect of BCG on the risk of leprosy.METHODSWe used a population-based case-control study of 20 leprosy confirmed cases reported among residents of Ciudad del Este, Paraguay, diagnosed in 2016-2017. Three controls were selected from a random sample of households from the city. We assessed vaccine effectiveness using 1- odds ratio [OR], and confounding for age, gender, education, occupation, and marital status using stratified and exact logistic regression, and explored if there was effect modification calculating the synergy factor (SF) and relative excess risk due to interaction (RERI).RESULTSAfter controlling for age, gender, education, occupation and marital status, the OR of BCG scar on the risk of leprosy was 0.10 (95% confidence interval [CI], 0.02 to 0.45), for an estimate of vaccine effectiveness of 89.5% reduced risk of leprosy (95% CI, 55.2 to 98.1). There was evidence of heterogeneity by which the effectiveness of BCG seemed stronger among younger persons (Breslow-Day and Z-test of the SF had a p<0.05), and both the RERI and SF indicated a less then multiplicative and additive interaction of BCG and younger age.CONCLUSIONSBCG vaccination was associated with a decreased risk of leprosy in the study population, particularly in persons born after 1980. -
SummaryKey Message
Paraguay had the second highest reported incidence in the Americas, but no previous study had investigated the topic of BCG for leprosy in Paraguay. We confirmed that BCG protected from leprosy, hence it may have contributed to the observed decline of leprosy.Citations
Citations to this article as recorded by
- Autoantibodies and vitamin D in leprosy patients in the Brazilian Amazon
Glaucielen Gomes da Silva, Tinara Leila de Souza Aarão, Lucas Corrêa Modesto, Luis Arthur Moreira Ferreira, Pablo Rodrigues Nunes de Souza, Rafael Malcher Meira Rocha, Luiz Fábio Magno Falcão, Juarez Antônio Simões Quaresma
BMC Infectious Diseases.2026;[Epub] CrossRef - An update of the diagnosis, treatment, and prevention of leprosy: A narrative review
Chien-Yuan Huang, Shih-Bin Su, Kow-Tong Chen
Medicine.2024; 103(34): e39006. CrossRef - Comparison of Antiphenolic Glycolipid-1 Antibody Levels in Seropositive Contacts of Leprosy after 2 Years of Single-dose Rifampicin as Postexposure Prophylaxis
Odelia Jovita Jusuf Fantoni, Rusmawardiana, Yulia Farida Yahya, Erial Bahar, Theresia Lumban Toruan, Muhammad Izazi Hari Purwoko
The International Journal of Mycobacteriology.2023; 12(4): 399. CrossRef - BCG and SARS-CoV-2—What Have We Learned?
Jakub Kulesza, Ewelina Kulesza, Piotr Koziński, Wojciech Karpik, Marlena Broncel, Marek Fol
Vaccines.2022; 10(10): 1641. CrossRef
First
Prev
